Details for New Drug Application (NDA): 050599
✉ Email this page to a colleague
NDA 050599 describes ILOSONE SULFA, which is a drug marketed by Lilly and is included in one NDA. Additional details are available on the ILOSONE SULFA profile page.
The generic ingredient in ILOSONE SULFA is erythromycin estolate; sulfisoxazole acetyl. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin estolate; sulfisoxazole acetyl profile page.
The generic ingredient in ILOSONE SULFA is erythromycin estolate; sulfisoxazole acetyl. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin estolate; sulfisoxazole acetyl profile page.
Summary for 050599
| Tradename: | ILOSONE SULFA |
| Applicant: | Lilly |
| Ingredient: | erythromycin estolate; sulfisoxazole acetyl |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SUSPENSION;ORAL | Strength | EQ 125MG BASE/5ML;EQ 600MG BASE/5ML | ||||
| Approval Date: | Sep 29, 1989 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
